American Express, Eli Lilly, and Live Nation featured on CNBC's Final Trades

1 min read Updated on 12 Jun 2026, 05:07 PM

Reviewed by

Radhika SScanX News Team

AI Summary

American Express reported Q1 revenue of $18.91 billion, driven by spending and net interest income. Eli Lilly secured FDA approval for EBGLYSS for atopic dermatitis treatment. Live Nation saw its price target raised to $200 by Morgan Stanley.

*this image is generated using AI for illustrative purposes only.

Jenny Van Leeuwen Harrington, CEO of Gilman Hill Asset Management, LLC, selected American Express Company on CNBC's Halftime Report Final Trades, citing the firm's recent financial performance. American Express reported upbeat first-quarter 2026 results on April 23, with quarterly revenue net of interest expense rising 10% year-over-year to $18.91 billion. This figure surpassed the analyst consensus estimate of $18.62 billion. The growth was driven by higher Card Member spending, increased net interest income, growth in card balances, and strong card fee growth.

Rob Sechan, CEO of NewEdge Wealth, named Eli Lilly and Company as his final trade. This recommendation follows an announcement on June 9 that the U.S. Food and Drug Administration approved the company's EBGLYSS (lebrikizumab-lbkz). The approval covers one maintenance dose every eight weeks for patients with moderate-to-severe atopic dermatitis.

Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, identified Live Nation Entertainment, Inc. as a stock approaching a new 52-week high. This outlook aligns with a Wednesday update from Morgan Stanley analyst Cameron Mansson-Perrone, who maintained an Overweight rating on the stock and increased the price target from $185 to $200.